




[TQx] Saxocell Conference

June 2026

STRICTLY CONFIDENTIAL

FROM CLASSICAL LENGTHY CAR-T CELL MANUFACTURING TO 5 HOURS TQx BED-SIDE PROCESS

TQx comparison to status-quo



€
200.000€

4-5 weeks



€
20.000€

5-6 hours

Note: CAPEX (e.g. Device costs, facilities...) are not included in the costs laid out

02.07.2026



DRUG DELIVERY SYSTEM ENABLES SAFE & EFFICACIOUS THERAPY APPLICATION, T-CELL SELECTIVITY DRIVES

SAFETY
TQx EXiVO™ Approach

TQx EXiVO™ GENERATED THERAPY AT THE PATIENTS BED SIDE


A. EX VIVO - Drug Delivery System

T-cell selection & automated extracorporeal of autologous donor T-cells (no CARs expressed)



FRESENIUS KABI
caring for life

2 Safety step =
T-Cell Selectivity



Bristol Myers Squibb

1 Collection of whole blood



2 Target cell selection



3 Genetic modification



4 Wash target cells & analyti



5 Reinfusion & CAR expressio



6 Retrospective analytics




5-6



Low

B. IN VIVO - In Patient

In vivo generation & activity of
CAR expressing T cells



TQx is leveraging well established technologies & approach is aligned with regulators (PEI)

OUR MODULAR CELLfinity PLATFORM UNLOCKS INFINITE CGT CLINICAL PROGRAM POSSIBILITIES FOR PHARMA

TQx CELLfinity Platform

CELLfinity PLATFORM	INDICATION	SELECTION MARKER	TRANSFECTION METHOD	INTEGRATION	TARGET / RECEPTOR
PIPELINE PROGRAM 01	Haemato-Oncology	T-Cells CD 3+	Viral Vectors	Transient	CD 19 CAR
PIPELINE PROGRAM 02	Autoimmune				BCMA CAR
PIPELINE PROGRAM 03	Infectious disease	B-Cells CD 19	LNPs	Stable	CD 22 CAR
PIPELINE PROGRAM 04	Neurology		Electroporation		TCR
PIPELINE PROGRAM 05	Solid tumors	NK Cells CD 56		Hybrid	CAAR
	Orphan disease		Mechanoporation		
	...	...	...	...	...


**TQx platform business model:**
Clinical-stage asset & process out-licensing model

TQx OFFERS THE ONLY SAFE *IN VIVO* CELL & GENE THERAPY TO PATIENTS IN NEED ACROSS INDICATIONS AT LOW COST



TQx OWN CLINICAL THERAPY (TQ-1001)

We aim to validate our TQx approach in a first clinical trial TQ-1001 starting Q4 2027. Goal is to be in the clinic as fast as possible and show significant clinical outcome



OUR TEAM CONSISTS OF EXPERTS IN CGT WITH COMPLEMENTARY SKILL-SETS



Dr. Christian Eckert
Co-Founder & CEO



Dr. Christian Stemberger
Co-Founder & CSO



Sabine Radisch
Co-Founder & CTO



Dr. Stefan Dreher
Co-Founder & COO



Christin Zündorf
Chief Business Officer



INVESTORS & FUNDING



SPRIN-D



ADVISORS



Prof. Mouggiakakos
University
Magdeburg



Prof. Krönke
Rheumatology
Charité Berlin



Prof Dr. med. Iris Löw-Friedrich
Biopharma
Executive



Tim Campbell
VP Early Clinical
Dev. CGT @BMS



Lorenz Mayr, Ph.D.
Ex-Biopharma
Executive